Haemorrhagic fever with renal syndrome bivalent vaccine (Changchun Institute of Biological Products)

双价肾综合征出血热灭活疫苗（长春生物制品研究所）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHaemorrhagic fever with renal syndrome bivalent vaccine (Changchun Institute of Biological Products)
Drug Alias Name汉普威
ClassificationVaccines > Vaccine type > Multivalent vaccineVaccines > National Immunization Program > Non-immunization program vaccine(Class II)Vaccines > Application > Prophylactic vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHemorrhagic Fever with Renal Syndrome
Global Approved IndicationsHemorrhagic Fever with Renal Syndrome
Approved Indications in ChinaHemorrhagic Fever with Renal Syndrome
Original Approved Country/TerritoryMainland China
Original Approved Date2002/07/19
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChangchun Institute Of Biological Products Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChangchun Institute Of Biological Products Co Ltd
Inactive CompaniesN/A
Active IndicationsHemorrhagic Fever with Renal Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeJ07BX
Related LinksN/A